SARS-CoV-2 Reduction

Dana Yee M.D, Sam Kabbani, MS, BS, MT(ASCP), Albert Brockman, and Kevin Noble
Innovative Bioanalysis, Inc.
Full Report


To evaluate the efficacy of the Defend 400 at reducing SARS-CoV-2, the virus causing COVID-19.


The test was conducted in a 20'x8'x8' (36m³) chamber that complied with BSL-3 standards. The temperature during all test runs was approximately 76 ±2°F (24.4 ±1.1°C), with a relative humidity of 33%. A 6.32 x 106 TCID50/mL of SARS CoV-2 in viral suspension media was nebulized into the room with mixing fans before collection. Air sample collections occurred at 0, 15, and 45 minutes of device operation.


The test results displayed a more rapid reduction in viral concentration than the natural viability loss rates observed. After 15 minutes of operation, the viral concentration decreased from a starting value of 6.32 x 106 TCID50/mL to 3.45 x 106, 3.19 x 106, and 3.00 x 106 TCID50/mL, averaging to approximately 3.21 x 106 TCID50/mL, a 49.20% reduction. With the device operating for 45 minutes, collectable SARS-CoV-2 decreased to an average of 8.76 x 103 TCID50/mL, a 99.86% reduction.


The Defend 400 demonstrated the ability to reduce the concentration of active SARS-CoV-2 from the air at a more rapid rate with an average of 49.20% reduction after 15 minutes and 99.86% after 45 minutes. A net reduction of 99.75% was achieved with the device operating for a total of the 45 minutes time point.

Defend 400 achieved 99.75% reduction of live SARS-CoV-2

Contact Us

USA Headquarters
3540 Toringdon Way, Suite 200 Charlotte, NC  28277
1 866 508 1118

Ireland Headquarters
DCU Innovation Campus
Old Finglas Road
Glasnevin, Dublin D11 KXN4
+353 1 907 2750